Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 2,120 trials

Chronic Lymphocytic Leukemia: New Triple Therapy Study

We are testing a new combination of medications for patients with high-risk chronic lymphocytic leukemia who haven't been treated before. The study aims to see if this new treatment can help keep the disease from progressing better than standard options.

High-Risk Hematological Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Preventing Diabetes After Kidney Transplant: GLP-1 Medication Study

We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.

Metabolic Syndrome in Kidney Transplant Patients3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology

Preventing Diabetes After Kidney Transplant: GLP-1 Treatment Study

We are studying whether a new medication can help prevent diabetes in patients immediately after receiving a kidney transplant. This trial looks at various health effects and safety over time.

Post-Kidney Transplant Diabetes>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDiabetologyNephrology

Ulcerative Colitis: Comparing Ustekinumab and Infliximab

We are studying whether a combination of two treatments helps people with moderate to severe ulcerative colitis achieve remission better than using each treatment alone.

Ulcerative Colitis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Teicoplanin for Infection Prevention in Pediatric AML

We are studying whether teicoplanin can help prevent serious infections in children newly diagnosed with acute myeloid leukemia. This trial will assess its safety and effectiveness during their treatment.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesOncology

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Acute Myeloid Leukemia: Bleximenib Treatment Study

We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.

Acute Myeloid Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Early Rectal Cancer: FARE Trial with [68Ga]Ga-FAPI-46 PET/CT

We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.

Rectal Cancer≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOtolaryngology

Severe Depression: Ketamine vs. Placebo

We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.

Major Depressive Disorder1-2 yearsConfirmation phase (III)Investigational MedicinesPsychiatry

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Alzheimer's Disease in Down Syndrome: Sleep and Temperature Study

We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.

Down SyndromeAlzheimer's Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurologyPsychiatry

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology